JBIO (JBIO) reported D&A of $9K in Q1 2026.

How has JBIO's D&A changed year-over-year?

JBIO's D&A increased by 125.0% year-over-year, from $4K to $9K.

What is the long-term trend for JBIO's D&A?

Over 4 years (2021 to 2025), JBIO's D&A has grown at a 14.7% compound annual growth rate (CAGR), from $15K to $26K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

JBIO JBIO D&A

D&A at other companies

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Travere Therapeutics, Inc.TVTX

$25.21M+96.9%

Vera TherapeuticsVERA

$140K+64.7%

AnaptysBio, Inc.ANAB

$130K-11.0%

Avalo TherapeuticsAVTX

$17K-87.4%

Cullinan Therapeutics, Inc.CGEM

$79K+3.9%

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's D&A?: JBIO (JBIO) reported D&A of $9K in Q1 2026.
How has JBIO's D&A changed year-over-year?: JBIO's D&A increased by 125.0% year-over-year, from $4K to $9K.
What is the long-term trend for JBIO's D&A?: Over 4 years (2021 to 2025), JBIO's D&A has grown at a 14.7% compound annual growth rate (CAGR), from $15K to $26K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.